Liankang Biotechnology Group (00690.HK): Bogutai? (Terripatide injection) application for marketing has been officially accepted by the State Food and Drug Administration
Interest income drives Q3 net profit to return to growth, and the "big and comprehensive" Lizhu Group increases profits but does not increase revenue | Read financial reports